ISA Pharmaceuticals Revenue and Competitors

Leiden,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ISA Pharmaceuticals's estimated annual revenue is currently $1.1M per year.(i)
  • ISA Pharmaceuticals's estimated revenue per employee is $155,000

Employee Data

  • ISA Pharmaceuticals has 7 Employees.(i)
  • ISA Pharmaceuticals grew their employee count by -89% last year.

ISA Pharmaceuticals's People

NameTitleEmail/Phone
1
CMC Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is ISA Pharmaceuticals?

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. SLP®immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP®lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP®immunotherapy portfolio targeting unmet medical needs in cancer and chronic infections, including tailored therapy for rare diseases. ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV. The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com SLP® and AMPLIVANT® are registered trademarks in Europe.

keywords:N/A

N/A

Total Funding

7

Number of Employees

$1.1M

Revenue (est)

-89%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ISA Pharmaceuticals News

2022-04-19 - Regeneron to Acquire Checkmate for $250M, Expanding ...

Regeneron Pharmaceuticals has agreed to acquire Checkmate ... cervical cancer in combination with ISA Therapeutics' ISA101b (all Phase II).

2022-04-19 - USD 812 Mn growth opportunity in Human Papillomavirus ...

ISA Pharmaceuticals BV; Merck and Co. Inc. Serum Institute of India Pvt. Ltd. Walvax Biotechnology Co. Ltd. Xiamen Innovax Biotech Co. Ltd...

2022-04-13 - ISA Pharmaceuticals announce new trial testing technology ...

A clinical trial of Amplivant – an adjuvant technology to boost immune response to cancer therapy –has started. ISA Pharmaceuticals' novel...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M717%N/A
#2
$1.4M717%N/A
#3
$1.7M1110%N/A
#4
$3.8M16129%$104M
#5
$3.3M186%N/A